Accepted for/Published in: JMIR Public Health and Surveillance
Date Submitted: May 7, 2025
Open Peer Review Period: May 13, 2025 - May 23, 2025
Date Accepted: Feb 24, 2026
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
An assessment of globally-accepted standards and benchmarks for tuberculosis surveillance — Philippines, 2023
ABSTRACT
Background:
The Philippines accounts for 7% of the global tuberculosis (TB) burden. In 2022, an estimated 741,000 Filipinos developed TB and 40,000 died as a result. Approximately 350,000 new TB diagnoses remain unreported annually.
Objective:
In October 2023, we undertook an assessment of the accuracy, completeness and timeliness of the national TB surveillance system using globally-accepted TB surveillance standards and benchmarks assessment tool.
Methods:
A team of Filipino and international evaluators conducted field visits to nine purposively selected health facilities across four regions. Health records were reviewed and key informants were interviewed to assess essential activities and best practices.
Results:
Among 16 applicable performance standards, four were fully met, nine were partially met, and three were not met. This was an improvement from a similar assessment conducted in 2019. Although electronic case-based recording and reporting had expanded greatly since 2019, large local variations in the adoption of quality assurance practices were evident. Over 60% of reported persons with TB had no bacteriological confirmation, despite a functional national laboratory network. Under-reporting due to underdiagnosis was also noted. Delayed reporting was common, especially in locations with limited internet connectivity or access to antituberculosis medications.
Conclusions:
Issues related to data quality assurance, gaps in case verification and timeliness emerged as potential threats to data integrity and surveillance fidelity. Enhanced monitoring and evaluation and tailored studies, such as a national TB inventory study, could assist in quantifying potential under-reporting and clinical overdiagnosis, guiding future funding, and assessing progress toward elimination targets. Clinical Trial: N/A
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.